CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma

CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma

Abstract Background Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein, we inv...

Descrición completa

Detalles Bibliográficos
Main Authors: Junya Yamaguchi, Fumiharu Ohka, Chalise Lushun, Kazuya Motomura, Kosuke Aoki, Kazuhito Takeuchi, Yuichi Nagata, Satoshi Ito, Nobuhiko Mizutani, Masasuke Ohno, Noriyuki Suzaki, Syuntaro Takasu, Yukio Seki, Takahisa Kano, Kenichi Wakabayashi, Hirofumi Oyama, Shingo Kurahashi, Kuniaki Tanahashi, Masaki Hirano, Hiroyuki Shimizu, Yotaro Kitano, Sachi Maeda, Shintaro Yamazaki, Toshihiko Wakabayashi, Yutaka Kondo, Atsushi Natsume, Ryuta Saito
Formato: Artigo
Idioma:English
Publicado: Wiley 2023-03-01
Series:Cancer Medicine
Subjects:
CD79B
MYD88
primary central nervous system lymphoma
rapid molecular diagnosis
R‐MPV
Acceso en liña:https://doi.org/10.1002/cam4.5512

Internet

https://doi.org/10.1002/cam4.5512

Títulos similares